Anti-platelet antibodies in a natural animal model of sulphonamide-associated thrombocytopaenia

References

• Bottiger LE, Westerholm B, Thrombocytopenia. I. Incidence and aetiology. Acta Med Scand 1972; 191: 535–540
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard U, Andersen M, Hansen PB. Thrombocytopenia induced by noncytotoxic drugs in Denmark 1968-91. J Intern Med 1996; 239: 509–515
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug-specific characteristics of thrombocytopenia caused by non-cytotoxic drugs. Eur J Clin Pharmacol 1998; 54: 701–706
   PubMed Web of Science ®Google Scholar
• Aster RH. Drug-induced immune cytopenias. Toxicology 2005; 209: 149–153
   PubMed Web of Science ®Google Scholar
• van den Bemt PM, Meyboom RH, Egberts AC. Drug-induced immune thrombocytopenia. Drug Safety 2004; 27: 1243–1252
   PubMed Web of Science ®Google Scholar
• Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355: 809–817
   PubMed Web of Science ®Google Scholar
• Tilles SA. Practical issues in the management of hypersensitivity reactions: Sulfonamides. South Med J 2001; 94: 817–824
   PubMed Web of Science ®Google Scholar
• van den Bemt PM, Meyboom RH, Egberts AC. Drug-induced immune thrombocytopenia. Drug Saf 2004; 27: 1243–1252
   PubMed Web of Science ®Google Scholar
• Kaufman DW, Kelly JP, Johannes CB, Sandler A, Harmon D, Stolley PD, Shapiro S. Acute thrombocytopenic purpura in relation to the use of drugs. Blood 1993; 82: 2714–2718
   PubMed Web of Science ®Google Scholar
• Cribb AE, Lee BL, Trepanier LA, Spielberg SP. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: Clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev 1996; 15: 9–50
   PubMed Web of Science ®Google Scholar
• Trepanier LA. Idiosyncratic toxicity associated with potentiated sulfonamides in the dog. J Vet Pharmacol Ther 2004; 27: 129–138
   PubMed Web of Science ®Google Scholar
• Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: A chemical, molecular, and clinical perspective. Chem Res Toxicol 1998; 11: 969–988
   PubMed Web of Science ®Google Scholar
• Daftarian MP, Filion LG, Cameron W, Conway B, Roy R, Tropper F, Diaz-Mitoma F. Immune response to sulfamethoxazole in patients with AIDS. Clinical and Diagnostic Laboratory Immunology 1995; 2: 199–204
   PubMedGoogle Scholar
• Meekins CV, Sullivan TJ, Gruchalla RS. Immunochemical analysis of sulfonamide drug allergy: Identification of sulfamethoxazole-substituted human serum proteins. J Allergy Clin Immunol 1994; 94: 1017–1024
   PubMed Web of Science ®Google Scholar
• Cribb AE, Pohl LR, Spielberg SP, Leeder JS. Patients with delayed-onset sulfonamide hypersensitivity reactions have antibodies recognizing endoplasmic reticulum proteins. J Pharmacol and Experi Therap 1997; 282: 1064–1072
   PubMed Web of Science ®Google Scholar
• Uetrecht J. Role of animal models in the study of drug-induced hypersensitivity reactions. AAPS J 2005; 7: 914–921
   Web of Science ®Google Scholar
• Curtis BR, McFarland JG, Wu GG, Visentin GP, Aster RH. Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood 1994; 84: 176–183
   PubMed Web of Science ®Google Scholar
• Kiefel V, Santoso S, Schmidt S, Salama A, Mueller-Eckhardt C. Metabolite-specific (IgG) and drug-specific antibodies (IgG, IgM) in two cases of trimethoprim-sulfamethoxazole-induced immune thrombocytopenia. Transfusion 1987; 27: 262–265
   PubMed Web of Science ®Google Scholar
• Trepanier LA, Danhof R, Toll J, Watrous D. Clinical findings in 40 dogs with hypersensitivity associated with administration of potentiated sulfonamides. J Vet Intern Med 2003; 17: 647–652
   PubMed Web of Science ®Google Scholar
• Burgess JK. Molecular mechanisms of drug-induced thrombocytopenia. Curr Opin Hematol 2001; 8: 294–298
   PubMed Web of Science ®Google Scholar
• Savage B, Bottini E, Ruggeri ZM. Interaction of integrin alpha IIb beta 3 with multiple fibrinogen domains during platelet adhesion. J Biol Chem 1995; 270: 28812–28817
   PubMed Web of Science ®Google Scholar
• Smith JW, Ruggeri ZM, Kunicki TJ, Cheresh DA. Interaction of integrins alpha v beta 3 and glycoprotein IIb-IIIa with fibrinogen. Differential peptide recognition accounts for distinct binding sites. J Biol Chem 1990; 265: 12267–12271
   PubMedGoogle Scholar
• Pidard D, Montgomery RR, Bennett JS, Kunicki TJ. Interaction of AP-2, a monoclonal antibody specific for the human platelet glycoprotein IIb-IIIa complex, with intact platelets. J Biol Chem 1983; 258: 12582–12586
   PubMed Web of Science ®Google Scholar
• Shattil SJ, Brass LF, Bennett JS, Pandhi P. Biochemical and functional consequences of dissociation of the platelet membrane glycoprotein IIb-IIIa complex. Blood 1985; 66: 92–98
   PubMed Web of Science ®Google Scholar
• Boudreaux MK, Lipscomb DL. Clinical, biochemical, and molecular aspects of Glanzmann's thrombasthenia in humans and dogs. Vet Pathol 2001; 38: 249–260
   PubMed Web of Science ®Google Scholar
• Choquet-Kastylevsky G, Vial T, Descotes J. Allergic adverse reactions to sulfonamides. Curr Allergy Asthma Rep 2002; 2: 16–25
   PubMedGoogle Scholar
• Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, Lind RN, Pereira J, Aster RH. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002; 100: 2071–2076
   PubMed Web of Science ®Google Scholar
• Brassard JA, Curtis BR, Cooper RA, Ferguson J, Komocsar W, Ehardt M, Kupfer S, Maurath C, Swabb E, Cannon CP, Aster RH. Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: Evidence for an immune etiology. Thromb Haemost 2002; 88: 892–897
   PubMed Web of Science ®Google Scholar
• Giugliano RP. Drug-induced thrombocytopenia: Is it a serious concern for glycoprotein IIb/IIIa receptor inhibitors?. J Thromb Thrombolysis 1998; 5: 191–202
   PubMed Web of Science ®Google Scholar
• Curtis BR, Divgi A, Garritty M, Aster RH. Delayed thrombocytopenia after treatment with abciximab: A distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2004; 2: 985–992
   PubMed Web of Science ®Google Scholar
• Curtis BR, Swyers J, Divgi A, McFarland JG, Aster RH. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2002; 99: 2054–2059
   PubMed Web of Science ®Google Scholar
• Kekomaki R. Platelet function and immune response. J Pediatr Hematol Oncol 2003; 25(Suppl 1)S19–23
   PubMedGoogle Scholar
• Gruchalla RS. Drug metabolism, danger signals, and drug-induced hypersensitivity. J Allergy Clin Immunol 2001; 108: 475–488
   PubMed Web of Science ®Google Scholar
• Ju C, Uetrecht JP. Mechanism of idiosyncratic drug reactions: Reactive metabolite formation, protein binding and the regulation of the immune system. Curr Drug Metab 2002; 3: 367–377
   PubMedGoogle Scholar
• Andersson PO, Wadenvik H. Chronic idiopathic thrombocytopenic purpura (ITP): Molecular mechanisms and implications for therapy. Expert Rev Mol Med 2004; 6: 1–17
   PubMedGoogle Scholar
• Gengozian N, Rice DT. Antibody-dependent cellular cytotoxicity with platelets as the target cell: Potential application to the study of immune thrombocytopenia. Clin Exp Immunol 1982; 47: 431–436
   PubMed Web of Science ®Google Scholar
• de Belder MA, Sutton AG. Abciximab (Reopro): A clinically effective glycoprotein IIb/IIIa receptor blocker. Expert Opin Investig Drugs 1998; 7: 1701–1717
   PubMedGoogle Scholar
• Visentin GP, Newman PJ, Aster RH. Characteristics of quinine- and quinidine-induced antibodies specific for platelet glycoproteins IIb and IIIa. Blood 1991; 77: 2668–2676
   PubMed Web of Science ®Google Scholar
• Aster RH. Can drugs cause autoimmune thrombocytopenic purpura?. Semin Hematol 2000; 37: 229–238
   PubMed Web of Science ®Google Scholar
• Lerner W, Caruso R, Faig D, Karpatkin S. Drug-dependent and non-drug-dependent antiplatelet antibody in drug-induced immunologic thrombocytopenic purpura. Blood 1985; 66: 306–311
   PubMed Web of Science ®Google Scholar
• Lavergne SN, Danhof RS, Volkman EM, Trepanier LA. Association of drug-serum protein adducts and anti-drug antibodies in dogs with sulphonamide hypersensitivity: A naturally occurring model of idiosyncratic drug toxicity. Clin Exp Allergy 2006; 36: 907–915
   PubMed Web of Science ®Google Scholar
• Kurian JR, Bajad SU, Miller JL, Chin NA, Trepanier LA. NADH cytochrome b5 reductase and cytochrome b5 catalyze the microsomal reduction of xenobiotic hydroxylamines and amidoximes in humans. J Pharmacol Exp Ther 2004; 311: 1171–1178
   PubMed Web of Science ®Google Scholar
• Trepanier LA, Miller JL. NADH-dependent reduction of sulphamethoxazole hydroxylamine in dog and human liver microsomes. Xenobiotica 2000; 30: 1111–1121
   PubMed Web of Science ®Google Scholar
• Bhaiya P, Roychowdhury S, Vyas PM, Doll MA, Hein DW, Svensson CK. Bioactivation, protein haptenation, and toxicity of sulfamethoxazole and dapsone in normal human dermal fibroblasts. Toxicology and applied pharmacology 2006; 215: 158–167
   PubMed Web of Science ®Google Scholar
• Hopkins JE, Naisbitt DJ, Humphreys N, Dearman RJ, Kimber I, Park BK. Exposure of mice to the nitroso metabolite of sulfamethoxazole stimulates interleukin 5 production by CD4 + T-cells. Toxicology 2005; 206: 221–231
   PubMed Web of Science ®Google Scholar